Published in Eur J Endocrinol on June 01, 2010
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab (2013) 1.05
Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol (2011) 1.05
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid (2013) 0.99
2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J (2012) 0.93
Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2. Clinics (Sao Paulo) (2012) 0.89
Multiple endocrine neoplasia type 2: achievements and current challenges. Clinics (Sao Paulo) (2012) 0.86
The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies. Orphanet J Rare Dis (2015) 0.83
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol (2016) 0.83
Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics (2011) 0.82
Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies. J Thyroid Res (2011) 0.81
Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway. Thyroid (2013) 0.81
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol (2013) 0.81
Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J Oncol (2012) 0.80
A differential diagnosis of inherited endocrine tumors and their tumor counterparts. Clinics (Sao Paulo) (2013) 0.77
Distribution of RET mutations in multiple endocrine neoplasia 2 in Denmark 1994-2014: a nationwide study. Thyroid (2016) 0.76
Clinical utility gene card for: multiple endocrine neoplasia type 2. Eur J Hum Genet (2011) 0.76
The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association. Thyroid Res (2013) 0.76
Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations. Sci Rep (2017) 0.75
Pediatric Medullary Thyroid Carcinoma. J Pediatr Oncol (2016) 0.75
Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey. J Clin Res Pediatr Endocrinol (2015) 0.75
Hereditary medullary thyroid carcinoma: the management dilemma. Fam Cancer (2012) 0.75
Genotype-Phenotype Correlation in Patients With Germline Mutations of VHL, RET, SDHB, and SDHD Genes: Thai Experience. Clin Med Insights Endocrinol Diabetes (2017) 0.75
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases. Mol Diagn Ther (2017) 0.75
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst (2005) 5.32
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 4.52
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med (2014) 4.00
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab (2008) 3.38
Cancer consequences of the Chernobyl accident: 20 years on. J Radiol Prot (2006) 3.03
Europe is iodine deficient. Lancet (2003) 2.99
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med (2006) 2.74
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab (2007) 2.74
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol (2008) 2.70
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Miner Res (2008) 2.66
Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid (2008) 2.65
Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol (2009) 2.59
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) (2006) 2.56
Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA (2008) 2.52
Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol (2013) 2.43
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab (2014) 2.38
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
Advances in the treatment of prolactinomas. Endocr Rev (2006) 2.31
Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension (2004) 2.31
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab (2013) 2.30
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery (2012) 2.29
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet (2010) 2.23
Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care (2012) 2.21
¹⁸F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging (2014) 2.21
Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA (2004) 2.20
Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients. J Hypertens (2008) 2.18
Endocrine disorders during the first year after autologous stem-cell transplant. Am J Med (2005) 2.14
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (2005) 2.13
Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability. Am J Hum Genet (2010) 2.12
Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens (2006) 2.09
An official ATS clinical policy statement: Congenital central hypoventilation syndrome: genetic basis, diagnosis, and management. Am J Respir Crit Care Med (2010) 2.07
Thyroglobulin measurement in fine-needle aspiration biopsy of metastatic lymph nodes after rhTSH stimulation. Head Neck (2011) 2.07
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab (2004) 2.01
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology (2005) 2.00
Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.98
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.95
Association between panic disorder, major depressive disorder and celiac disease: a possible role of thyroid autoimmunity. J Psychosom Res (2002) 1.94
miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell Physiol (2005) 1.93
Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care (2002) 1.92
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab (2010) 1.86
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab (2011) 1.86
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst (2004) 1.84
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab (2004) 1.82
Identification of new variants of human BMP15 gene in a large cohort of women with premature ovarian failure. J Clin Endocrinol Metab (2006) 1.81
Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid (2014) 1.81
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab (2002) 1.81
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res (2012) 1.80
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.79
Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol (2003) 1.79
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol (2003) 1.79
Prevalence and functional significance of antipituitary antibodies in patients with autoimmune and non-autoimmune thyroid diseases. J Clin Endocrinol Metab (2007) 1.78
Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. Am J Hum Genet (2008) 1.77
Premature ovarian failure. Orphanet J Rare Dis (2006) 1.75
Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab (2004) 1.75
Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care (2003) 1.75
Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol (2011) 1.74
The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) (2007) 1.73
Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet (2004) 1.72
Familial dysalbuminemic hyperthyroxinemia: a persistent diagnostic challenge. Clin Chem (2009) 1.71
Luteinizing hormone signaling in preovulatory follicles involves early activation of the epidermal growth factor receptor pathway. Mol Endocrinol (2008) 1.71
Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. Surgery (2002) 1.71
Signaling by internalized G-protein-coupled receptors. Trends Pharmacol Sci (2010) 1.70
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70